• Executive interview - Race Oncology

    721 views 2 years ago
    Race Oncology is developing bisantrene, which had been the subject of over 40 clinical trials in the 1980s and 1990s as part of Lederle’s search for a safer anthracycline chemotherapy. Despite positive responses in a variety of cancers, especially AML (it was even approved for the treatment of AML in France, but never commercialised), development stopped after Lederle was sold to Wyeth and then Wyeth to Pfizer. Race will be developing bisantrene initially for relapsed/refractory AML and expects to start a pivotal trial for approval in the US around the end of 2018. Show less
    Read more
  • Uploads Play all

    • Fund manager interview – UIL - Duration: 2 minutes, 38 seconds.

      • 2 days ago
      • No views
      UIL (LSE:UTL) is a closed-end, Bermuda-incorporated investment company, managed by specialist investment manager ICM. Day-to-day management of the fund is the responsibility of Charles Jillings. He...
    • Executive interview – Avacta Group - Duration: 4 minutes, 33 seconds.

      • 1 week ago
      In this video, Alastair Smith, CEO of Avacta Group, discusses the progress the company has made this year. This includes new and expanded partnerships, operational and financial achievements, and t...
    • Bitesize briefing – Heavy oil in Guyana - Duration: 3 minutes, 14 seconds.

      • 1 week ago
      This video looks at the implications of the recent heavy oil discoveries offshore Guyana.

      See more at: https://www.edisongroup.com/our-content/
    • Executive interview – Wheaton Precious Metals - Duration: 6 minutes, 25 seconds.

      • 1 week ago
      Wheaton Precious Metals was founded in 2004. The company’s vision is to be the world’s premier precious metals investment vehicle. The streaming model Wheaton employs offers shareholders many advan...
    • Bitesize briefing – CVC Credit Partners European Opportunities - Duration: 6 minutes, 59 seconds.

      • 2 weeks ago
      In this video, Milosz Papst presents the company profile, investment strategy and recent performance of CVC Credit Partners European Opportunities, which invests predominantly in a diversified port...
    • Executive interview - Kazia Therapeutics - Duration: 5 minutes, 6 seconds.

      • 2 weeks ago
      Kazia Therapeutics has presented very encouraging initial efficacy data from the dose-ranging stage of its current Phase II trial. The data are sufficient to give Kazia confidence that it can run a...
    • Executive interview – Actinogen Medical - Duration: 9 minutes, 7 seconds.

      • 2 weeks ago
      Actinogen Medical is an ASX-listed biotech developing its lead asset Xanamem, a specific 11β-HSD1 inhibitor designed to treat cognitive impairment that occurs in chronic neurodegenerative and metab...
    • Executive interview - Seneca Global Income & Growth Trust - Duration: 7 minutes, 49 seconds.

      • 3 weeks ago
      Seneca Global Income & Growth Trust (LSE:SIGT) was launched in 2005 and adopts a ‘multi-asset value investing’ approach, aiming to generate income and capital growth with low volatility by investin...
    • Executive interview – OTC Markets Group - Duration: 12 minutes.

      • 3 weeks ago
      OTC Markets Group operates the OTCQX, OTCQB and Pink financial markets for over 10,000 US and global securities. OTC Link LLC, a member of FINRA, operates OTC Link ATS and OTC Link ECN, both SEC-re...
    • Executive interview – Canadian General Investments - Duration: 4 minutes, 56 seconds.

      • 3 weeks ago
      Canadian General Investments (LSE:CGI and TSE:CGI) was launched in 1930, it is North America’s second-oldest closed-end fund. Since 1956, it has been managed by Morgan Meighen & Associates. Portfol...
    • Executive interview – Picton Property Income - Duration: 7 minutes, 44 seconds.

      • 3 weeks ago
      Picton Property Income is an internally managed UK REIT that invests in a diversified portfolio of commercial property across the UK. It aims to be one of the consistently best-performing, diversif...
    • Executive interview - VolitionRX discusses Q319 results and provides a business update - Duration: 7 minutes, 56 seconds.

      • 4 weeks ago
      Volition is a multinational life sciences company developing simple, easy-to-use, cost-effective blood tests to help diagnose a range of cancers and other diseases in the human and animal health ma...
    This item has been hidden
  • This item has been hidden
to add this to Watch Later

Add to

Loading playlists...